Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICAFUNGIN IN SODIUM CHLORIDE 0.9% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Micafungin is an echinocandin antifungal that inhibits the synthesis of 1,3-beta-D-glucan, an essential component of the fungal cell wall, leading to osmotic instability and cell death.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Treatment of candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses,Treatment of esophageal candidiasis,Prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
100 mg intravenously once daily for invasive candidiasis; 150 mg intravenously once daily for esophageal candidiasis.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Terminal elimination half-life is approximately 13-20 hours in adults; supports once-daily dosing. Half-life is prolonged in moderate-to-severe hepatic impairment (Child-Pugh B/C) but no dosage adjustment is required.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Micafungin is metabolized by arylsulfatase and catechol-O-methyltransferase (COMT) to the M1 metabolite, and further metabolized by CYP3A4 to M2; however, CYP3A4 plays a minor role. The drug is not a significant inhibitor or inducer of CYP enzymes.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Primarily biliary/fecal (≈71% of administered dose recovered in feces as parent drug and metabolites); renal excretion accounts for ≈15% (urine: <1% as unchanged drug).
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Highly protein-bound (≥99.8%), primarily to albumin; slight binding to α1-acid glycoprotein.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Volume of distribution at steady state (Vss) is approximately 0.2-0.3 L/kg in adults; indicates limited tissue distribution, primarily confined to plasma and interstitial fluid.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Only available as intravenous infusion; oral bioavailability is negligible (<0.1%) due to poor gastrointestinal absorption.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
No dosage adjustment required for any degree of renal impairment.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
In moderate hepatic impairment (Child-Pugh B), reduce dose to 100 mg once daily; no data for severe impairment (Child-Pugh C). No adjustment for mild impairment.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
For invasive candidiasis: 2 mg/kg (max 100 mg) intravenously once daily for patients ≥40 kg; 2 mg/kg once daily for patients <40 kg. For esophageal candidiasis: 3 mg/kg (max 150 mg) once daily.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
No specific dose adjustment; use standard adult dosing based on renal and hepatic function.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
There is no FDA black box warning for micafungin.
None
Hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions,Hepatic effects: elevations in liver enzymes, bilirubin, and rare cases of hepatic necrosis or hepatitis,Renal effects: elevations in serum creatinine and BUN,Hematologic effects: hemolytic anemia, leukopenia, thrombocytopenia,Injection site reactions: phlebitis, thrombophlebitis,Photosensitivity and risk of skin malignancies in patients with prolonged exposure
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypersensitivity to micafungin or any component of the formulation
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No known food interactions. Grapefruit and grapefruit juice do not interact with micafungin.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Micafungin is classified as FDA Pregnancy Category C. In animal studies, embryotoxicity and skeletal abnormalities were observed at doses 0.04 times the human dose. No adequate human studies exist. First trimester: Theoretical risk based on animal data; use only if benefit justifies risk. Second/third trimester: Limited data; may be used if clearly needed due to lack of alternative therapy.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Unknown if micafungin is excreted in human milk. Due to high molecular weight (ca. 1292 Da) and high protein binding (>99%), excretion is likely minimal. M/P ratio not determined. Caution advised; consider alternative therapy or temporarily discontinue breastfeeding during infusion.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Pregnancy-induced physiological changes (increased plasma volume, enhanced renal clearance) may alter pharmacokinetics. However, specific dose adjustment guidelines are unavailable. Standard adult dosing (100-200 mg/day for invasive candidiasis) is typically used; monitor clinical response and serum drug levels if available.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Micafungin is an echinocandin antifungal that inhibits beta-(1,3)-D-glucan synthase. Administer IV only; do not bolus. Monitor hepatic function due to risk of elevated transaminases. Caution in patients with moderate to severe hepatic impairment (Child-Pugh B/C). Use with caution in patients with hypersensitivity to other echinocandins. May increase sirolimus and nifedipine levels; monitor levels. No renal dose adjustment needed. Do not mix with other drugs in same infusion line.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
This medication is given intravenously to treat serious fungal infections.,Report any signs of allergic reaction: rash, itching, difficulty breathing, swelling of face or throat.,Monitor for symptoms of liver problems: jaundice, dark urine, abdominal pain, unexplained fatigue.,Inform your doctor about all medications you take, including over-the-counter drugs and supplements.,You may have blood tests to monitor liver function during treatment.,Do not drive or operate heavy machinery if you experience dizziness or confusion.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Micafungin, an echinocandin antifungal, inhibits CYP3A4 and P-glycoprotein, thereby decreasing the hepatic and intestinal metabolism of Lercanidipine, a CYP3A4 substrate. This leads to increased plasma concentrations of Lercanidipine, potentially causing excessive vasodilation, hypotension, reflex tachycardia, and peripheral edema. In severe cases, this interaction may precipitate syncope, myocardial ischemia, or acute kidney injury due to hypoperfusion."
"Rifapentine, a potent inducer of hepatic CYP450 enzymes and drug transporters, paradoxically increases serum concentrations of micafungin, an echinocandin antifungal. This interaction is thought to occur via inhibition of micafungin's biliary excretion and possibly through competitive binding to plasma proteins, leading to reduced clearance and elevated trough levels. Clinically, this may increase the risk of micafungin-related hepatotoxicity and requires close monitoring of liver function and therapeutic drug monitoring if available."
"Micafungin, a potent inhibitor of CYP3A4 and a substrate of CYP3A4, may reduce the hepatic clearance of Perhexiline, a CYP3A4 substrate with a narrow therapeutic index. Co-administration can result in elevated serum concentrations of Perhexiline, increasing the risk of hepatotoxicity and peripheral neuropathy. This interaction is significant as it may lead to adverse outcomes including liver injury and neurological deficits."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICAFUNGIN IN SODIUM CHLORIDE 0.9% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
MICAFUNGIN IN SODIUM CHLORIDE 0.9% is a Electrolyte that works by Micafungin is an echinocandin antifungal that inhibits the synthesis of 1,3-beta-D-glucan, an essential component of the fungal cell wall, leading to osmotic instability and cell death.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICAFUNGIN IN SODIUM CHLORIDE 0.9% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICAFUNGIN IN SODIUM CHLORIDE 0.9% is: 100 mg intravenously once daily for invasive candidiasis; 150 mg intravenously once daily for esophageal candidiasis.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICAFUNGIN IN SODIUM CHLORIDE 0.9% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICAFUNGIN IN SODIUM CHLORIDE 0.9% is classified as Category A/B. Micafungin is classified as FDA Pregnancy Category C. In animal studies, embryotoxicity and skeletal abnormalities were observed at doses 0.04 times the human dose. No adequate hum. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.